ANI PHARMACEUTICALS, INC Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
ANI PHARMACEUTICALS, INC (ANIP) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of -$31.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2026-08-07
- ANI PHARMACEUTICALS, INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2026-06-30 was -$31.00K, a 103.38% decline year-over-year.
- ANI PHARMACEUTICALS, INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2026-03-31 was $218.00K, a 72.78% decline year-over-year.
- ANI PHARMACEUTICALS, INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-12-31 was $275.00K.
- ANI PHARMACEUTICALS, INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-09-30 was -$4.58M, a 655.27% decline year-over-year.
- ANI PHARMACEUTICALS, INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2025 was -$2.59M.
- ANI PHARMACEUTICALS, INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2024 was -$630.00K, a 144.18% decline from fiscal 2023.
- ANI PHARMACEUTICALS, INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2023 was $1.43M, a 62.05% decline from fiscal 2022.
- ANI PHARMACEUTICALS, INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2022 was $3.76M, a 1779.00% increase from fiscal 2021.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$31.00K 10-Q · filed 2026-08-07 | $187.00K 10-Q · filed 2026-08-07 | $462.00K derived: sum of 3 quarters · filed 2026-08-07 | -$4.12M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $218.00K 10-Q · filed 2026-05-08 | $493.00K derived: sum of 2 quarters · filed 2026-05-08 | -$4.09M derived: sum of 3 quarters · filed 2026-05-08 | -$3.17M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $275.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$4.31M derived: sum of 2 quarters · filed 2026-02-27 | -$3.39M derived: sum of 3 quarters · filed 2026-08-07 | -$2.59M 10-K · filed 2026-02-27 |
| 2025-09-30 | -$4.58M 10-Q · filed 2025-11-07 | -$3.66M derived: sum of 2 quarters · filed 2026-08-07 | -$2.86M 10-Q · filed 2025-11-07 | -$4.77M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $917.00K 10-Q · filed 2026-08-07 | $1.72M 10-Q · filed 2026-08-07 | -$186.00K derived: sum of 3 quarters · filed 2026-08-07 | $639.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $801.00K 10-Q · filed 2026-05-08 | -$1.10M derived: sum of 2 quarters · filed 2026-05-08 | -$278.00K derived: sum of 3 quarters · filed 2026-05-08 | $81.00K derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$1.08M derived: sum of 2 quarters · filed 2026-02-27 | -$720.00K derived: sum of 3 quarters · filed 2026-02-27 | -$630.00K 10-K · filed 2026-02-27 |
| 2024-09-30 | $825.00K 10-Q · filed 2025-11-07 | $1.18M derived: sum of 2 quarters · filed 2025-11-07 | $1.27M 10-Q · filed 2025-11-07 | $3.26M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $359.00K 10-Q · filed 2025-08-08 | $449.00K 10-Q · filed 2025-08-08 | $2.43M derived: sum of 3 quarters · filed 2025-08-08 | -$121.00K derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $90.00K 10-Q · filed 2025-05-09 | $2.08M derived: sum of 2 quarters · filed 2025-05-09 | -$480.00K derived: sum of 3 quarters · filed 2025-05-09 | $555.00K derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $1.99M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$570.00K derived: sum of 2 quarters · filed 2025-02-28 | $465.00K derived: sum of 3 quarters · filed 2025-02-28 | $1.43M 10-K · filed 2025-02-28 |
| 2023-09-30 | -$2.56M 10-Q · filed 2024-11-08 | -$1.52M derived: sum of 2 quarters · filed 2024-11-08 | -$559.00K 10-Q · filed 2024-11-08 | $1.06M derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $1.03M 10-Q · filed 2024-08-06 | $2.00M 10-Q · filed 2024-08-06 | $3.62M derived: sum of 3 quarters · filed 2024-08-06 | $6.10M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $961.00K 10-Q · filed 2024-05-10 | $2.58M derived: sum of 2 quarters · filed 2024-05-10 | $5.06M derived: sum of 3 quarters · filed 2024-05-10 | $3.97M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $1.62M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $4.10M derived: sum of 2 quarters · filed 2024-02-29 | $3.00M derived: sum of 3 quarters · filed 2024-02-29 | $3.76M 10-K · filed 2024-02-29 |
| 2022-09-30 | $2.48M 10-Q · filed 2023-11-08 | $1.38M derived: sum of 2 quarters · filed 2023-11-08 | $2.13M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | -$1.09M 10-Q · filed 2023-08-09 | -$342.00K 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | $753.00K 10-Q · filed 2023-05-08 | |||
| 2021-12-31 | $200.00K 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |